8-K: NextCure Announces Full Year 2024 Financial Results and Business Update, Highlighting Progress of LNCB74 Clinical Trial

NextCure reports full year 2024 financial results, provides a business update, and anticipates funding operations into the second half of 2026.

Summary

• NextCure, a clinical-stage biopharmaceutical company, announced its full year 2024 financial results and provided a business update on March 6, 2025.
• The company completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plans to initiate backfill cohorts in the second half of 2025.
• NextCure's cash, cash equivalents, and marketable securities totaled $68.6 million as of December 31, 2024, which is expected to fund operations into the second half of 2026.
• Research and development expenses were $41.5 million for the full year ended December 31, 2024, compared to $47.9 million for the full year ended December 31, 2023.
• General and administrative expenses were $15.7 million for the full year ended December 31, 2024, compared to $19.7 million for the full year ended December 31, 2023.
• The net loss for the full year ended December 31, 2024, was $55.7 million, compared to a net loss of $62.7 million for the full year ended December 31, 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is making progress with its clinical trials and managing its expenses, but it is still operating at a loss and has seen a decrease in cash reserves.

Positives

• NextCure completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers.
• The company expects current financial resources to fund operating expenses and capital expenditures into the second half of 2026.
• Research and development expenses decreased year-over-year.
• General and administrative expenses decreased year-over-year.
• The net loss decreased year-over-year.

Negatives

• The company experienced a decrease in cash, cash equivalents, and marketable securities from $108.3 million in 2023 to $68.6 million in 2024.
• The company reported a net loss of $55.7 million for the full year ended December 31, 2024.

Risks

• The company's future success depends on the progress and results of clinical trials.
• The company may need to obtain additional financing on acceptable terms or at all.
• The company's ability to maintain its listing on the Nasdaq Global Select Market is a risk factor.
• The company depends on key personnel.

Future Outlook

NextCure expects its current financial resources to fund operating expenses and capital expenditures into the second half of 2026 and plans to initiate backfill cohorts in the Phase 1 trial of LNCB74 in the second half of 2025.

Management Comments

• In 2024 we reprioritized our resources to advance our antibody-drug conjugate (ADC) program and recently completed cohort 1 of the Phase 1 study evaluating LNCB74 as a potential therapeutic for treating multiple cancers.
• We look forward to additional progress in 2025, including initiating backfill cohorts in the second half of the year, said Michael Richman, NextCures president and CEO.

Industry Context

NextCure is operating in the competitive biopharmaceutical industry, focusing on developing novel therapies for cancer. The company's focus on antibody-drug conjugates (ADCs) aligns with a growing trend in cancer treatment, as ADCs offer targeted delivery of cytotoxic agents to tumor cells. The company is also exploring non-oncology programs, such as Alzheimer's disease and osteogenesis imperfecta, which diversifies its pipeline and reduces its reliance on the oncology market.

Comparison to Industry Standards

• NextCure's cash runway into the second half of 2026 is a positive sign, but it's crucial to compare this with the cash burn rates of similar clinical-stage biopharmaceutical companies.
• For example, companies like Mersana Therapeutics or ImmunoGen, which are also focused on ADCs, have similar cash positions but may have different burn rates depending on the stage and number of their clinical programs.
• The decrease in R&D expenses could be viewed positively if it reflects increased efficiency, but it's important to ensure that this doesn't compromise the progress of key clinical programs.
• Compared to industry benchmarks, NextCure's G&A expenses appear reasonable, but further analysis would be needed to assess their efficiency relative to peers.

Stakeholder Impact

• Shareholders: The company's progress in clinical trials and financial stability are positive for shareholders.
• Employees: The company's continued operations provide job security for employees.
• Patients: The company's development of new cancer therapies could benefit patients who do not respond to current treatments.

Next Steps

• Initiate backfill cohorts in the Phase 1 trial of LNCB74 in the second half of 2025.
• Seek partnering opportunities for preclinical non-oncology programs (NC181 and NC605).

Key Dates

Keywords

LNCB74, B7-H4 ADC, clinical trial, financial results, NextCure, biopharmaceutical, cancer, ADC